Ashleigh Palmer, Provention Bio CEO
November 18, 2022 07:17 AM ESTUpdated November 21, 05:26 AM
FDA+

Up­dat­ed: Proven­tion prices drug to de­lay type I di­a­betes at $193K as FDA nod kicks off US launch with Sanofi

Amber Tong

For the first time, the FDA has ap­proved a drug to de­lay the on­set of type I di­a­betes, po­ten­tial­ly giv­ing chil­dren, teenagers and young adults …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times